HONOLULU- A team of University of Hawaii Cancer Center scientists have created a new type of anti-cancer drug, named BP-1-102 that targets a key protein that triggers the development of many types of cancer including lung, breast, and skin cancers. The development of BP-1-102 was guided by the research teams computer based molecular analysis of the cancer causing Stat 3 protein that causes cancer by promoting abnormal cell growth in otherwise healthy cells.
A unique feature of BP-1-102 is that it remains highly effective against cancer even when administered in oral form. Presently, most anti-cancer drugs require intravenous (IV) administration in a clinic or hospital setting which increases the financial, physical and emotional burdens on cancer patients. In its experimental form, BP-1-102 has shown promise in treating breast and lung cancers. The research article is published in the May 22nd edition of the Proceedings of the National Academy of Sciences.